Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202522422

H1N1 Influenza: Epidemiology, Surveillance, and Laboratory Diagnosis—Implications for Public Health Practice

Mohammed Awadh AlMaliki [(1)] , Yasser Ali Abdu Doshi [(2)] , Ahmed Abduh Ahmed Hamzi [(3)] , Adeeb Abdullatif Alshuwaier [(4)] , Ali Mohammed Shrahili [(5)] , Mohammed Abdullah Almarshud [(6)] , Nayef Mansour Al-Shaitan [(7)] , Jabril Yousef Ahmed Abdali [(8)] , Mohammed Ahmad Othman Naseeb [(9)] , Mohammad Abdullah M Alrehaili [(10)]

(1) Riyadh Cluster One,Ministry of Health, Saudi Arabia,
(2) Arish General Hospital In Jazan,Ministry of Health, Saudi Arabia,
(3) Alaradh Primary Health Care Center,Ministry of Health, Saudi Arabia,
(4) King Salman Center For Kidney Diseases,Ministry of Health, Saudi Arabia,
(5) Tuwaiq Al , Gharbi Health Center In Riyadh,Ministry of Health, Saudi Arabia,
(6) Qassim Health Cluster Alrabieia,Ministry of Health, Saudi Arabia,
(7) Interior Riyadh Azm, Saudi Arabia,
(8) Primary Health Care Center,Ministry of Health, Saudi Arabia,
(9) Farasan General Hospital,Ministry of Health, Saudi Arabia,
(10) Qassim - Al-Qawara General Hospital,Ministry of Health, Saudi Arabia

Abstract

Background: H1N1 influenza, a subtype of influenza A virus, is a highly transmissible respiratory illness with pandemic potential. Its emergence in 2009 highlighted the interplay between viral evolution, zoonotic transmission, and global public health preparedness.

Aim: To review the epidemiology, virology, clinical features, diagnostic strategies, and management of H1N1 influenza, emphasizing implications for surveillance and prevention.

Methods: A comprehensive literature-based analysis was conducted, synthesizing historical data, virologic characteristics, epidemiologic patterns, and clinical management strategies documented during the 2009 pandemic and subsequent outbreaks.

Results: H1N1 influenza demonstrates genetic plasticity through antigenic drift and shift, enabling reassortment across swine, avian, and human hosts. The 2009 pandemic infected up to 24% of the global population, causing an estimated 151,700–575,500 deaths. Clinical presentation ranges from mild upper respiratory illness to severe viral pneumonia and ARDS, with complications including bacterial superinfection and multisystem involvement. Laboratory confirmation relies on RT-PCR, supported by serology and culture. Early antiviral therapy with neuraminidase inhibitors significantly reduces morbidity and mortality, while vaccination remains the cornerstone of prevention. Integrated "One Health" surveillance and occupational risk mitigation are essential to limit zoonotic spillover and pandemic emergence.

Conclusion: H1N1 influenza exemplifies the dynamic nature of influenza epidemiology and underscores the need for coordinated global strategies encompassing surveillance, vaccination, and timely antiviral intervention to reduce disease burden and prevent future pandemics.

Keywords: H1N1 influenza, pandemic, epidemiology, reassortment, antiviral therapy, One Health, public health preparedness

Introduction

H1N1 influenza, a subtype of influenza A virus, is a communicable viral illness capable of producing a broad spectrum of respiratory disease in humans, ranging from self-limited upper respiratory tract infection to, in a subset of cases, clinically significant lower respiratory tract involvement. The clinical presentation classically resembles an influenza-like illness and may include rhinorrhea, cough, reduced appetite, fever, rigors, myalgia, and headache, with some patients additionally developing lower respiratory tract disease or gastrointestinal manifestations.[1][2][3] Symptom severity is influenced by host factors such as age, immune status, pregnancy, and comorbid cardiopulmonary conditions, as well as by viral factors that affect tissue tropism and replication efficiency. Although multiple influenza strains circulate globally, influenza A and B viruses account for the predominant burden of seasonal and epidemic influenza in humans, with influenza A being particularly notable for its capacity to undergo major antigenic shifts that can precipitate pandemics. From a virologic and ecological perspective, influenza A viruses are characterized by

*Corresponding author e-mail: m7md3321@hotmail.com (Mohammed Awadh AlMaliki).
Receive Date: 01 December 2025, Revise Date: 28 December 2025, Accept Date: 31 December 2025

remarkable genetic plasticity, enabling them to circulate in multiple animal reservoirs and to generate novel strains through reassortment. Among swine populations, three subtypes of swine influenza are described as circulating worldwide—H3N2, H1N2, and H1N1—reflecting the dynamic interplay of influenza lineages within pig herds and across regions. The term "swine influenza" is used to denote influenza viruses that primarily circulate in pigs, yet the public health relevance becomes acute when such viruses acquire the capacity to infect humans. The global prominence of H1N1 influenza increased dramatically with the emergence of the 2009 pandemic, during which a novel influenza A(H1N1) virus—frequently referred to in media as "swine flu"—was identified in humans after reassortment events involving swine influenza viruses and preexisting influenza strains.[4] This episode highlighted how animal–human interfaces can facilitate the emergence of genetically distinct viruses capable of efficient spread in people, with consequential implications for surveillance, laboratory preparedness, and outbreak response.

The 2009 H1N1 virus was understood to have arisen through recombination and reassortment among diverse influenza lineages, including prior swine, avian, and human strains, resulting in a virus with antigenic properties sufficiently distinct from circulating seasonal strains to permit widespread susceptibility. Such genetic mixing is of particular concern in influenza A because the segmented RNA genome allows exchange of gene segments when a host is co-infected by different strains, producing progeny viruses with novel constellations of surface antigens and internal proteins. The 2009 pandemic, therefore, became a prominent example of how reassortment can generate a virus with enhanced capacity to replicate and spread within human populations.[4] Beyond its clinical impact, the outbreak also exerted substantial social and economic effects, influencing public behavior and impacting industries such as food production and tourism, in part due to heightened risk perception and evolving public messaging during an unfolding global event. The relationship between swine influenza and human disease is shaped by both veterinary and occupational health realities. H1N1 influenza contributes to respiratory illness in pigs by infecting the respiratory tract, and outbreaks in swine can occur with high attack rates within herds. Human infections linked to swine exposure—often described as zoonotic "swine flu"—have historically been associated with close contact with infected pigs, including in agricultural settings, live animal markets, and exhibition environments. These zoonotic events underscore that pigs can act as hosts in which influenza viruses adapt and diversify, with potential spillover into humans. Importantly, swine influenza viruses may infect humans more readily if antigenic characteristics shift through reassortment among different influenza strains, a process that can enhance replication and transmission dynamics.[5] In practical terms, such shifts can yield viruses that are immunologically unfamiliar to a large portion of the human population, thereby increasing the probability of sustained spread after an initial zoonotic introduction.

Reassortment is not merely a theoretical mechanism; it has repeatedly been associated with historically consequential influenza events. Influenza pandemics arise when a novel influenza A virus emerges to which humans have little preexisting immunity and when that virus attains the capacity for efficient person-to-person transmission. Reassortment between animal and human influenza strains can facilitate such emergence by combining gene segments that confer human receptor binding, robust replication, and transmissibility. This evolutionary pathway has been linked to major global outbreaks, including those in 1918 and 2009, when influenza viruses acquired the capability for sustained human transmission.[6] The 2009 event, in particular, illustrated how rapidly an emergent influenza strain can disseminate internationally in the context of modern mobility, placing extraordinary demands on clinical systems, public health surveillance, and laboratory diagnostics to track spread, characterize severity, and guide mitigation strategies. The historical benchmark for H1N1-related global impact remains the 1918 pandemic, commonly referred to as the Spanish flu, which is widely recognized as one of the most devastating infectious disease events in recorded history. The 1918 H1N1 influenza virus is estimated to have infected approximately 500 million people globally and to have caused between 50 and 100 million deaths, corresponding to roughly 3% to 5% of the world's population at that time.[7] These figures have been used to emphasize both the extraordinary transmissibility of pandemic influenza and its capacity to produce severe outcomes at population scale. While the determinants of severity in 1918 were multifactorial—including viral virulence, host susceptibility patterns, wartime conditions, and limited medical countermeasures—its legacy continues to influence pandemic preparedness frameworks. The scale of illness and mortality remains a central rationale for investing in surveillance systems capable of detecting novel influenza strains early and for maintaining laboratory capacity to characterize viruses rapidly.

In 2009, the World Health Organization formally classified the outbreak of influenza A(H1N1) as a pandemic, reflecting sustained global transmission and widespread susceptibility.[8] The 2009 H1N1 virus primarily spread through respiratory droplets generated by infected individuals, consistent with typical influenza transmission pathways, with the potential contribution of indirect transmission via fomites when contaminated surfaces are touched and the virus is subsequently transferred to mucosal surfaces of the nose, mouth, or eyes.[9]

The rapid worldwide spread drew attention to the overlapping clinical features of influenza across hosts. Notably, similarities in the manifestations of H1N1 infection in humans and pigs were described during the pandemic, a finding plausibly related to shared aspects of viral pathogenesis and to the genetic reassortment processes that contributed to the emergence of the virus.[4][10] Such observations are epidemiologically relevant because they reinforce the need for integrated "One Health" thinking in influenza preparedness, in which veterinary surveillance and human public health surveillance inform each other to detect unusual patterns of illness early. The 2009 pandemic also revealed how misinformation and misunderstandings can shape public response, risk perception, and economic outcomes during infectious disease events. A widely circulated misconception was that swine flu could be acquired through consumption of pork products such as bacon or ham. However, the virus is primarily localized to the respiratory tract, and transmission via properly handled and cooked food products is considered unlikely.[11] Despite this, the association between the term "swine flu" and food safety concerns contributed to measurable commercial repercussions, particularly for food-related industries and tourism, as consumers and travelers altered behavior in response to perceived risk.[12] This episode underscored the critical role of clear, evidence-informed communication in outbreak settings—not only to protect health but also to minimize unnecessary social disruption and economic harm. For public health professionals, epidemiologists, and laboratory specialists, H1N1 influenza therefore represents more than a virologic subtype: it is a recurring case study in how viral evolution, cross-species transmission, clinical variability, and public communication intersect to shape the real-world impact of an epidemic or pandemic.[1][2][3][4][5][6][7][8][9][10][11][12]

Etiology

The H1N1 influenza virus is a member of the Orthomyxoviridae family and is classified as an influenza A virus distinguished by its specific surface glycoprotein subtype. Structurally, it is an enveloped virion containing a single-stranded, negative-sense ribonucleic acid (RNA) genome. Viral particles typically measure approximately 80 to 120 nm in diameter, and the genome length is about 13.5 kb. A defining feature of influenza A viruses, including H1N1, is their segmented genome, which is composed of eight distinct RNA segments. This segmentation is epidemiologically and biologically important because it enables reassortment when different influenza viruses co-infect the same host, facilitating the emergence of novel strains with altered transmissibility, antigenicity, or virulence. The eight genomic segments collectively encode 11 proteins that coordinate viral entry, replication, assembly, immune evasion, and egress. Among the most clinically and immunologically salient components are the envelope proteins hemagglutinin (HA) and neuraminidase (NA), which are the principal antigens used to define influenza A subtypes.[13] The viral replication machinery is mediated by RNA polymerase components, including PB2, PB1, PB1-F2, PA, and PB, which together form the RNA-dependent RNA polymerase complex required for transcription and replication of the viral genome. Matrix proteins M1 and M2 play key structural and functional roles: M1 contributes to virion architecture and assembly, whereas M2 functions as an ion channel that facilitates uncoating and regulates the internal pH environment during entry.[14] Nonstructural proteins NS1 and NS2 (also termed NEP) further enhance viral fitness; NS1 is particularly important for antagonizing host innate immune responses, and NS2/NEP supports nuclear export of viral ribonucleoprotein complexes, both of which are crucial for efficient replication and pathogenesis.



Fig. 1: Electron microscope of H1N1 virus particles.

H1N1 influenza A is differentiated from other influenza A subtypes, such as H1N2, by the specific combination of HA and NA glycoproteins expressed on the viral surface, which operate in coordinated and metabolically synergistic fashion to optimize infectivity and propagation.[15] Hemagglutinin initiates infection by binding to sialic acid residues on host cell surfaces; this interaction can also mediate erythrocyte agglutination, a property exploited in laboratory assays.[16] Binding of HA enables viral attachment and subsequent internalization via endocytosis. Following endosomal uptake, acidification triggers conformational changes in HA that permit membrane fusion, while matrix-associated processes facilitate uncoating, thereby releasing viral ribonucleoprotein complexes into the host cell.[17] Once released, the viral RNA-

dependent polymerase initiates transcription and replication, allowing synthesis of viral proteins and new genome segments. Neuraminidase becomes critical during the later stages of infection: by cleaving sialic acid receptors, NA prevents newly formed virions from aggregating at the cell surface and promotes efficient budding and dissemination to neighboring cells.[18] Through this coordinated sequence—attachment, entry, replication, assembly, and release—H1N1 maintains transmission capacity and pathogenic potential across susceptible host populations.

Epidemiology

The epidemiology of H1N1 influenza is inseparable from its ecology at the human–animal interface and the evolutionary dynamics that allow influenza A viruses to persist, diversify, and periodically re-emerge in populations with limited immunity. Historically, the H1N1 influenza virus was first isolated from pigs in the 1930s by investigators in the United States, after which it became widely recognized by pork producers and veterinarians as an important cause of influenza-like illness in swine herds globally.[19] This early identification in pigs established swine as a critical host species in the broader influenza ecosystem, not only because infections can be maintained within swine populations over time, but also because the management practices of pig husbandry facilitate efficient within-herd transmission. As surveillance and clinical recognition improved, it became increasingly apparent that the swine and human influenza landscapes were not isolated; rather, they were linked through bidirectional transmission events and shared occupational and environmental risk factors. Human infections associated with swine exposure have been documented among individuals with close or repeated contact with pigs, including farmers, veterinarians, abattoir workers, and others involved in animal handling. Such zoonotic events have long been recognized, and epidemiologic observations also demonstrate the converse phenomenon: pigs may acquire human influenza viruses from infected handlers, thereby introducing human-adapted viral gene segments into swine populations.[20] This bidirectional flow is epidemiologically important because it creates opportunities for reassortment when pigs are co-infected with multiple influenza strains. Pigs have been described as particularly conducive hosts for reassortment because they may be susceptible to influenza viruses of avian and human origin, allowing the mixing of gene segments that can generate novel variants with altered transmissibility, antigenic features, or virulence potential.[20] Consequently, swine populations can function as an interface where viral evolution is accelerated by population density, repeated introductions of diverse strains, and ongoing selection pressures in both animal and human hosts.

At the population level, influenza epidemiology is strongly shaped by antigenic drift, a process driven by the accumulation of mutations—particularly in surface proteins—that progressively reduces the effectiveness of preexisting host immunity.[21] In practical terms, selection pressure in human populations with partial immunity to established influenza lineages encourages the emergence of variants with altered antigenic structure, enabling reinfections and sustaining seasonal circulation.[21] Antigenic drift underlies the recurrent nature of influenza epidemics and is a central rationale for ongoing virologic surveillance and periodic reformulation of influenza vaccines. Drift also complicates the epidemiologic interpretation of immunity, because exposure history does not confer durable protection when antigenic distance between prior and current strains is substantial. As a result, population susceptibility fluctuates over time and varies geographically, depending on patterns of prior exposure, vaccination coverage, and the speed at which new variants disseminate. In contrast to drift, antigenic shift refers to more abrupt and substantial changes in envelope proteins that can yield viruses sufficiently novel to evade immunity at the population level and thereby facilitate widespread transmission.[21] Such shifts are commonly linked to reassortment events, in which influenza viruses exchange genome segments and produce progeny with new combinations of hemagglutinin and neuraminidase. From an epidemiologic standpoint, antigenic shift is particularly consequential because it can transform a zoonotic spillover risk into a pandemic threat if the emergent virus achieves efficient human-to-human transmission. The 2009 H1N1 pandemic is a prominent modern example of this phenomenon, widely described as originating in Mexico and arising through complex reassortment involving multiple influenza lineages.[22][23] The emergent strain incorporated genetic contributions from Eurasian avian-like H1N1, avian H1N1, and a previously reassorted lineage composed of avian H1N1, human H3N2, and swine influenza viruses, illustrating how multi-lineage mixing can culminate in a virus capable of global dissemination.[22][23] The speed with which the 2009 virus spread underscored the vulnerability created by global mobility and emphasized the need for integrated surveillance systems capable of rapidly detecting novel strains and monitoring their epidemiologic behavior.

Quantifying the impact of pandemics requires methods that account for under-ascertainment, variability in testing, and differences in health system capacity across regions. Revised global estimates of the 2009 H1N1 pandemic suggested that, during the first 12 months, approximately 151,700 to 575,500 respiratory and cardiac deaths occurred, reflecting substantial mortality attributable to both direct viral pneumonia

and downstream cardiopulmonary complications.[22][23] These estimates also highlight the methodological reality that confirmed laboratory deaths capture only a subset of the true burden, necessitating modeling approaches to infer excess mortality. Seroprevalence studies further suggested extensive global dissemination, with estimates indicating that up to 24% of the world's population may have been infected during the pandemic's first year, a figure that emphasizes both the high attack rate and the broad susceptibility that followed the emergence of a novel strain.[22][23] Epidemiologically, the 2009 pandemic also reinforced that influenza burden is not uniformly distributed; rather, it is mediated by age structure, comorbidities, pregnancy, access to care, and the timing of mitigation measures, all of which influence infection risk and severity across communities. The historical reference point for H1N1's pandemic potential remains the 1918 influenza pandemic, which infected approximately 500 million people worldwide and caused an estimated 50 to 100 million deaths, making it among the deadliest infectious disease events in recorded history.[24] Although the social and biomedical context of 1918 differs markedly from contemporary conditions, the scale of that pandemic continues to shape public health preparedness paradigms. Importantly, the 2009 H1N1 virus has been described as a progeny of the strain implicated in the 1918 pandemic, reflecting the persistence and evolutionary continuity of influenza lineages across decades.[25] This lineage continuity underscores a central epidemiologic lesson: influenza viruses do not "disappear" in a simple sense, but may persist in animal reservoirs, diversify through drift and reassortment, and later reappear in human populations under favorable ecological and immunologic conditions.

Influenza A's long-term evolutionary trajectory also illustrates how descendants of historically significant strains can contribute to recurrent seasonal epidemics. While variants continue to persist in pigs, viral descendants of the 1918 virus have also been recognized to infect humans and to contribute to seasonal influenza epidemiology through lineages that include strains such as H2N2 and H3N2.[26] This perspective highlights that seasonal influenza is not an epidemiologically static entity; it is the product of continuous viral evolution and population immunity dynamics. Consequently, the boundary between "pandemic" and "seasonal" influenza is not solely virologic but also immunologic and epidemiologic, depending on whether the population has sufficient preexisting immunity to limit widespread impact. Interspecies transmission remains a recurring feature of influenza epidemiology. Influenza strains, including H1N1, have been noted to transmit between pigs and humans with relative frequency, although sustained human-to-human transmission of zoonotic swine-origin strains is generally uncommon.[27] The 2009 H1N1 strain represented an exception in that it was readily transmitted between pigs and humans and, crucially, sustained efficient person-to-person spread in humans.[28] This dual capacity has substantial implications for surveillance because it means that monitoring cannot be limited to either human or animal populations in isolation. Instead, integrated approaches are required to detect early signs of cross-species emergence and to characterize whether a newly detected strain is likely to establish ongoing human transmission. The role of swine as reservoirs further complicates the epidemiologic landscape. The persistence of influenza virus strains in swine after they decline or disappear in humans effectively positions pigs as a reservoir in which viruses can be maintained over time.[29] This reservoir function matters because it allows influenza strains to endure outside the human population and later re-emerge, either through reassortment events that generate new antigenic combinations, through waning immunity in human communities, or through a combination of both.[29] As viral strains circulate and diversify within swine populations, genetic diversity increases, creating a broader "library" of segments that can contribute to new variants. These dynamics support the continued development of novel strains with the potential to threaten susceptible human populations, thereby sustaining a cycle of emergence risk that extends beyond any single outbreak.[3][30] From a public health standpoint, this reinforces the importance of One Health surveillance, occupational risk mitigation for those working with pigs, robust laboratory capacity for subtyping and genomic characterization, and epidemiologic systems capable of rapidly detecting unusual clusters that may signal a shift in transmissibility or severity.[3][30]

Pathophysiology

H1N1 influenza is an acute viral illness characterized by infection of the respiratory epithelium, most commonly involving the upper respiratory tract, with the potential to extend into the tracheobronchial tree and lower respiratory tract in more severe cases.[2][31] Following exposure, viral particles attach to epithelial cells lining the nasopharynx and conducting airways, initiating a localized infection that can trigger inflammation of the upper passages and trachea and, in some patients, progress to involve distal bronchioles and alveolar structures.[2][31] The degree to which disease remains confined to the upper airway versus advancing to the lower respiratory tract reflects a complex interaction between viral replication dynamics, host immune responses, and preexisting host vulnerabilities such as chronic cardiopulmonary disease or immunosuppression. The temporal evolution of infection is clinically and epidemiologically important because it determines

when symptoms appear, when individuals are contagious, and how long isolation precautions are warranted. For the 2009 H1N1 influenza strains, the incubation period has a median duration of approximately two days, with a reported range from one to seven days.[32] During this pre-symptomatic interval, viral replication begins soon after inoculation and occurs primarily along the epithelial surfaces of the upper and, in some cases, lower respiratory passages. In most patients, viral replication and viral load rise rapidly and peak around 48 hours after infection, corresponding to the early symptomatic phase and aligning with the period in which transmission risk is often highest.[32] These kinetics help explain why influenza outbreaks can accelerate quickly in communities: a relatively short incubation period coupled with early high viral burden supports efficient spread before individuals recognize illness and adopt protective behaviors.



Fig. 2: H1N1 Virus structure.

Transmission potential is further amplified by the timing of infectiousness relative to symptom onset. The infectious period is reported to begin approximately one day before symptoms develop and to continue for about five to seven days after symptom onset.[33][34] This pre-symptomatic contagiousness has important implications for public health control because it limits the effectiveness of interventions that rely exclusively on symptom-based screening. Viral shedding, which correlates closely with infectiousness, is not uniform across age groups and immune states. Children may shed virus for longer durations—up to approximately 15 days—reflecting higher viral loads, prolonged replication, and behavioral factors that facilitate transmission.[35] In immunocompromised individuals, viral shedding can be markedly prolonged, persisting for weeks to months, consistent with impaired viral clearance and sustained replication.[36] These extended shedding periods are clinically relevant because they may require individualized infection-control planning and may increase the risk of onward transmission within households and healthcare settings. In routine cases, however, a commonly recommended isolation duration is approximately seven days, intended to encompass the typical infectious window for most immunocompetent adults.[34] Clinically, the pathophysiology of uncomplicated H1N1 infection is dominated by the host's innate immune response to viral replication. Acute symptoms generally persist for around three days, although reported durations range from one to eleven days.[2] The illness is typically self-limited in otherwise healthy individuals, yet systemic symptoms such as malaise and respiratory symptoms such as cough may persist for up to two weeks in some cases, reflecting ongoing epithelial recovery and post-inflammatory airway hyperreactivity. In a subset of patients, disease severity escalates, and hospitalization may become necessary; clinically significant deterioration is often observed within four to five days after symptom onset, a time course consistent with progression from upper airway infection to lower respiratory involvement or the development of complications.[37] The symptomatic "viral syndrome" associated with influenza—including high fever, coryza, and myalgia—is largely attributable to the host immune reaction, particularly the interferon response and downstream cytokine signaling.[38] Interferons and other mediators promote an antiviral state in infected and neighboring cells and recruit immune effector mechanisms, but they also drive systemic manifestations such as fever, fatigue, anorexia, and diffuse musculoskeletal pain. Thus, many hallmark symptoms of influenza represent the physiological cost of mounting an effective antiviral response rather than direct tissue destruction alone. At the same time, excessive or dysregulated inflammatory responses can contribute to tissue injury, increase vascular permeability, and impair gas exchange when lower respiratory involvement develops.

Severe complications arise when viral replication and host inflammatory responses extend beyond the upper airway, particularly in populations with reduced physiologic reserve or heightened vulnerability. Individuals with chronic lung disease, underlying cardiac conditions, and pregnant patients face increased risk of severe outcomes, including viral pneumonia, secondary bacterial pneumonia, hemorrhagic bronchitis, and, in the most severe cases, fatal disease.[39] These complications may develop rapidly and, in some cases, manifest within 48 hours of symptom onset, underscoring that early clinical assessment and close monitoring are essential in high-risk groups.[39] Viral pneumonia results from infection and inflammation of distal airway and alveolar structures, leading to impaired oxygenation and potentially acute respiratory distress. Superimposed bacterial pneumonia can occur when viral damage to respiratory epithelium and disruption of mucociliary clearance create a permissive environment for bacterial invasion, while hemorrhagic bronchitis reflects severe airway inflammation and mucosal injury. Collectively, these pathophysiologic pathways explain the broad clinical spectrum of H1N1 influenza, from self-limited upper

respiratory illness to rapidly progressive lower respiratory tract disease requiring hospitalization and intensive supportive care.[2][31][32][33][34][35][36][37][38][39]

Histopathology

The histopathologic substrate of H1N1 influenza reflects the virus's primary tropism for the respiratory tract and the host's inflammatory response to infection. The upper and lower airways constitute the principal anatomic compartments in which viral replication, epithelial injury, and downstream immune-mediated tissue effects occur. In mild clinical disease, the pathologic footprint within the respiratory tract is often limited, and gross or microscopic abnormalities may be subtle or even minimal. By contrast, severe infection—particularly when complicated by viral pneumonia or acute respiratory distress syndrome (ARDS)—can be associated with striking, diagnostically relevant pulmonary and airway lesions. This spectrum is consistent with clinical variability: localized epithelial infection may produce predominantly functional symptoms with modest structural disruption, whereas progressive lower respiratory involvement can result in diffuse tissue damage and impaired gas exchange. In the conducting airways, H1N1-associated lesions often include multifocal epithelial injury with destruction and possible desquamation of pseudo-columnar and columnar epithelial cells, reflecting direct viral cytopathic effects and inflammatory injury.[32] The submucosa may demonstrate prominent vascular congestion (hyperemia) and edema, consistent with increased vascular permeability and inflammatory mediator release.[32] These changes may be accompanied by luminal exudates and mucosal swelling that contribute to airflow limitation and cough. At the level of bronchioles, thrombus formation has been described and may represent a microvascular response to endothelial activation and inflammation.[32] In some cases, acute inflammation is particularly severe, producing hemorrhagic tracheobronchitis and desquamative bronchiolitis, findings that signal extensive mucosal injury, capillary leakage, and disruption of epithelial integrity. When inflammation and injury are intense, necrosis of the bronchiolar wall may occur; this necrotizing process can be followed by infiltration of polymorphonuclear leukocytes (polymorphs) and mononuclear cells into the affected tissues, reflecting the transition from acute neutrophil-dominant inflammation to mixed inflammatory cellularity as the immune response evolves.

Although influenza virions can be visualized by electron microscopy, histopathologic changes alone are generally considered nonspecific and cannot reliably distinguish H1N1 from other viral pneumonias without ancillary testing. Accordingly, tissue-based diagnosis typically requires correlation with additional laboratory modalities that directly detect the virus or host response. Confirmatory approaches include viral isolation via culture, serologic assessment, molecular detection using polymerase chain reaction (PCR), and immunohistochemistry to localize viral antigens in tissue sections (see Image. Electron Microscopic View of H1N1 Influenza Virus Particles).[40] This diagnostic principle is particularly important in critically ill patients, where multiple pathogens can produce overlapping histologic patterns and where treatment and infection control depend on etiologic certainty. In cases of H1N1 influenza pneumonia, the lung parenchyma may show characteristic features of viral-mediated alveolar injury and diffuse inflammatory response. Interstitial edema is a common early finding and may be accompanied by an inflammatory infiltrate, reflecting cytokine-driven vascular permeability and immune cell recruitment.[41] Within alveolar spaces, proteinaceous exudation may accumulate, and formation of hyaline membranes can occur—features that align with the exudative phase of diffuse alveolar damage and the clinicopathologic framework of ARDS.[41] Microvascular involvement may be evident through thrombosis of capillaries, which can exacerbate ventilation–perfusion mismatch and contribute to hypoxemia. Structural damage may extend to necrosis of alveolar septae, intra-alveolar hemorrhage, and loss of normal alveolar architecture.[41] Cytologic evidence of epithelial injury can be marked: desquamated pneumocytes with pyknotic nuclei may be displaced into alveolar spaces, reflecting severe cellular stress, apoptosis, or necrosis.[41] Infiltration by lymphocytes and histiocytes into the interstitium is often described, supporting the concept that viral pneumonia is not solely a neutrophilic process but involves prominent mononuclear inflammation that can contribute to interstitial thickening and impaired diffusion.

As disease progresses, late-stage histopathologic findings may reflect repair, remodeling, and, in some patients, persistent injury that transitions into a fibroproliferative phase. Patients may demonstrate ongoing diffuse alveolar damage alongside fibrosis, indicating the deposition of extracellular matrix and architectural remodeling that can reduce lung compliance and prolong respiratory failure.[41] Hyperplasia of type II pneumocytes is a frequent reparative response, as these cells proliferate to restore the alveolar epithelial barrier and to replace injured type I pneumocytes. Epithelial regeneration may be accompanied by squamous metaplasia, a change that reflects adaptive remodeling under conditions of chronic injury but can also signal aberrant repair. Collectively, these changes correspond to the fibroproliferative stage of ARDS and may be associated with diffuse alveolar destruction, prolonged ventilator dependence, and

persistent functional impairment even after viral clearance. Importantly, the presence and extent of fibrosis and epithelial remodeling are influenced by the duration of severe disease, intensity of inflammation, and the effectiveness of supportive care. A further histopathologic and clinical complexity in severe H1N1 infection is the frequent coexistence of bacterial coinfection or secondary bacterial pneumonia, which can modify tissue patterns and worsen outcomes. Coinfections may be present contemporaneously with viral pneumonia or may develop after initial viral injury disrupts mucociliary clearance and compromises innate defense mechanisms. Among bacteria commonly isolated in association with influenza pneumonia are Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus—including community-acquired and methicillin-resistant strains—and Haemophilus influenzae.[42] In such cases, histopathology may demonstrate a superimposed neutrophil-rich bronchopneumonia pattern, with dense intra-alveolar suppuration and consolidation, alongside viral-associated interstitial changes. The ability to recognize bacterial superinfection has practical implications for antimicrobial decision-making and for interpreting clinical deterioration that occurs after an initial influenza-like illness, particularly when new consolidation, leukocytosis, or purulent secretions emerge.

Overall, the histopathology of H1N1 influenza spans a continuum from modest airway epithelial injury in mild disease to severe necrotizing tracheobronchitis, bronchiolitis, and diffuse alveolar damage in life-threatening pneumonia and ARDS. While certain patterns—such as epithelial desquamation, interstitial edema, hyaline membrane formation, microthrombosis, and type II pneumocyte hyperplasia—are consistent with severe viral lung injury, they remain insufficiently specific to establish H1N1 as the etiologic agent without adjunctive diagnostic confirmation.[32][40][41] For laboratory specialists, this underscores the necessity of integrating histopathologic interpretation with molecular and immunohistochemical techniques, while for epidemiologists and public health professionals, it highlights how severe outcomes often reflect the combined effects of viral injury, host inflammatory responses, and bacterial coinfection dynamics that shape population-level morbidity and mortality.[42]

History and Physical

The clinical history and physical presentation of H1N1 swine influenza encompass a broad spectrum of disease severity, extending from mild, self-limited upper respiratory tract illness to fulminant lower respiratory tract complications and death. This variability is determined by an interplay of host susceptibility and exposure factors, including age, baseline cardiopulmonary reserve, the presence of chronic comorbidities, pregnancy status, influenza vaccination history, and the degree of preexisting or naturally acquired immunity to antigenically related influenza strains.[2] Consequently, careful clinical assessment must begin with an appreciation that symptom intensity and disease trajectory cannot be reliably predicted from the initial complaint alone, particularly early in the course when manifestations may be indistinguishable from other viral syndromes. In most cases, patients present with signs and symptoms that resemble seasonal influenza. Common features include fever, chills, cough, rhinorrhea, sore throat, conjunctivitis, myalgia, headache, nasal congestion, fatigue, and decreased appetite, with some individuals also describing dyspnea, pleuritic chest discomfort, presyncope or near-fainting, abdominal discomfort, and unintentional weight loss.[2] The overlap with seasonal influenza is substantial, and the practical implication is that clinical suspicion for H1N1 should not rely on any single symptom but rather on the constellation of findings and the epidemiologic context. Comparative observations suggest that, relative to typical seasonal influenza, H1N1 may be associated with more frequent cough, more prominent muscle pain, and pleural chest pain, which may reflect greater lower airway irritation or early pulmonary involvement in some patients.[43] Notably, during the 2009 pandemic, gastrointestinal symptoms were reported more frequently than is typical for many seasonal influenza strains; vomiting and diarrhea, in particular, were more commonly observed and may have contributed to dehydration, electrolyte imbalance, and perceived illness severity.[44] These gastrointestinal features are clinically relevant because they can mimic acute gastroenteritis or abdominal pathology, potentially delaying recognition of an underlying respiratory viral infection if respiratory symptoms are initially mild.

Because clinical manifestations overlap with a wide range of respiratory and systemic conditions, a detailed and structured history is critical to support differentiation of H1N1 influenza from other etiologies. Clinicians should elicit symptom onset timing, progression, exposure history, and the presence of high-risk features such as rapidly worsening dyspnea, chest pain, altered mental status, and poor oral intake. Epidemiologic risk assessment remains particularly important in suspected H1N1 cases, especially in the context of known exposure to confirmed H1N1 infection or recent travel to high-prevalence areas, as such information can meaningfully raise pretest probability and influence decisions regarding diagnostic testing, empiric antiviral therapy, and infection-control precautions. Attention should also be directed to vaccination status and prior influenza-like illness, as these may shape susceptibility and disease expression, while also informing public health reporting and contact tracing priorities. Severe disease during the 2009 H1N1 pandemic was clinically notable for a high

burden of lower respiratory complications. In the most serious cases, respiratory failure and shock were leading proximate causes of death, reflecting progression to severe viral pneumonia, acute respiratory distress syndrome, and systemic inflammatory decompensation.[37] Critically ill patients frequently demonstrated rapid escalation of oxygen requirements and may have required mechanical ventilation and intensive supportive care. Beyond respiratory failure, reported sequelae included encephalopathy and delirium, which can occur in severe systemic illness and may also reflect hypoxia or metabolic disturbances; cerebrovascular events such as stroke; gastrointestinal bleeding; secondary bacterial sepsis; myocardial infarction; decompensated cardiac failure; myocarditis; and acute kidney injury severe enough to require renal replacement therapy.[45] This multisystem involvement underscores that severe influenza is not solely a pulmonary disease but can precipitate widespread organ dysfunction through combined effects of hypoxemia, inflammatory signaling, hemodynamic instability, and secondary infections.

Epidemiologic patterns during the 2009 pandemic also differed from those typical of many seasonal influenza epidemics. Unlike seasonal strains that often disproportionately impact older adults, the 2009 H1N1 virus was associated with relatively more severe cases and fatalities among children and adults aged 60 years and younger.[46] This age distribution is consistent with the concept that older cohorts may have had partial immune protection due to prior exposure to antigenically related viruses, whereas younger populations lacked such cross-protective immunity and therefore experienced higher susceptibility and, in some contexts, greater severity. Such patterns highlight the importance of incorporating age-stratified risk into triage decisions and public health messaging during novel influenza outbreaks. Risk stratification is further refined by recognition of specific host factors associated with severe outcomes. During the 2009 pandemic, pregnancy—particularly in the second and third trimesters—was identified as a major risk factor, likely reflecting physiological changes in cardiopulmonary function and immune modulation that increase vulnerability to hypoxemic respiratory illness.[39][47] Obesity, especially with a body mass index of 35 kg/m² or higher, was also associated with increased risk, plausibly due to reduced respiratory reserve, chronic inflammation, and associated metabolic comorbidities.[39][47] Chronic medical conditions significantly increased susceptibility to severe disease, including chronic obstructive pulmonary disease, bronchial asthma, immunosuppression, chronic liver disease, neurologic disorders, and diabetes mellitus. Finally, delayed initiation of antiviral therapy—specifically oseltamivir started five or more days after symptom onset—was associated with worse outcomes, reinforcing the clinical principle that early antiviral treatment is most beneficial in high-risk patients and those with progressive symptoms.[39][47] Collectively, thorough history taking and careful physical examination, integrated with epidemiologic context and risk factor assessment, are essential to identify patients at risk for deterioration and to guide timely diagnostic and therapeutic interventions.[2][37][39][43][44][45][46][47]



Fig. 3: Symptoms of H1N1 viral infection.

Evaluation

Influenza A (H1N1) infection can present in a range of clinical contexts, from outpatient influenza-like illness to severe acute respiratory infection requiring hospitalization and critical care. This variability means that evaluation must be tailored to both the clinical syndrome and the epidemiologic setting. In practice, H1N1 should remain an important differential diagnosis in patients with otherwise unexplained fever and respiratory symptoms, particularly during periods of confirmed influenza activity or when clusters of acute pneumonia occur in a community. Consideration is especially warranted in patients with acute pneumonia of unclear etiology, rapidly progressive hypoxemia, or systemic features disproportionate to initial upper respiratory complaints, as influenza can initiate a viral pneumonitis that predisposes to secondary bacterial infection and multisystem complications. The first step is typically a standardized clinical assessment including vital signs, pulse oximetry, and evaluation for respiratory distress, followed by routine laboratory and imaging investigations to characterize severity and to identify alternative or concurrent diagnoses. Initial investigations commonly include hematologic, microbiologic, biochemical, and radiologic testing to support diagnosis and risk stratification. A complete blood count may demonstrate leukopenia, leukocytosis, or lymphopenia, findings that are nonspecific but useful for assessing inflammatory burden and considering bacterial coinfection. Basic metabolic panels assist in identifying dehydration,

electrolyte abnormalities, renal dysfunction, or metabolic derangements that may complicate respiratory illness. Where severe disease is suspected, arterial or venous blood gas analysis can help quantify gas exchange impairment and acid–base status. Microbiologic evaluation may include bacterial cultures, urinary antigen testing where relevant, or multiplex respiratory pathogen panels when available, particularly in hospitalized patients in whom distinguishing viral from bacterial processes guides antimicrobial stewardship and cohorting decisions. Radiologic assessment, most often with chest radiography, is essential when lower respiratory tract involvement is suspected; it can reveal patterns consistent with viral pneumonia, focal consolidation suggesting bacterial superinfection, or diffuse infiltrates consistent with evolving acute respiratory distress syndrome.

Definitive confirmation of influenza A (H1N1) requires direct testing of an appropriate respiratory specimen. Recommended specimens include nasopharyngeal swabs, aspirates, or washes, with selection influenced by patient age, clinical severity, and feasibility of collection. Multiple laboratory techniques can be applied to these samples. Reverse transcriptase polymerase chain reaction (RT-PCR) is widely regarded as a principal diagnostic method because of its sensitivity and specificity, and because it can identify influenza A and, depending on assay design, discriminate subtypes.[48][49] Viral isolation by culture remains a valuable reference method for virologic characterization and surveillance, although it is slower and less directly useful for time-sensitive clinical decisions. Additional methods may include complement fixation testing, haemagglutination assays, and immunofluorescence-based antibody detection, each of which carries distinct performance characteristics and use cases.[48][49] Serologic evaluation can also contribute, particularly when acute respiratory samples were not obtained or when a retrospective diagnosis is required. Convalescent serology may be performed to demonstrate seroconversion—often described as a transition from detectable immunoglobulin M (IgM) responses to IgG—or to document a four-fold increase in influenza virus–specific IgG antibody titers between acute and convalescent samples.[48][49] While such serologic approaches can support epidemiologic investigations and confirm prior infection, they are generally less useful for immediate clinical management because results are delayed. Point-of-care rapid tests can provide timely information, but their interpretive limitations must be understood. Although rapid antigen-based assays are often specific for human influenza viruses, their sensitivity can be variable, and importantly, they do not consistently detect zoonotic variants.[50] This limitation is particularly relevant for surveillance at the human–animal interface, where non-seasonal or swine-origin viruses may circulate. Consequently, negative rapid test results do not reliably exclude influenza in high-suspicion cases, and confirmatory molecular testing may be necessary when clinical features, exposure history, or outbreak context indicate elevated pretest probability.

The possibility of a novel or zoonotic swine-origin influenza virus may be suggested when an influenza A virus is detected but does not match expected molecular targets or antigenic patterns associated with typical human influenza strains, including differences in hemagglutinin characterization. In such circumstances, diagnosis may sometimes be established retrospectively through serologic testing, but this approach is complicated by cross-reactivity between antibodies elicited by human influenza viruses and those generated in response to related swine-origin strains.[51] Cross-reactivity can blur interpretive boundaries, particularly when antigenic similarity exists between the HA and neuraminidase (NA) proteins of swine influenza viruses and those of ancestral human viruses. This is epidemiologically plausible because some swine influenza lineages may derive surface proteins from viruses that previously circulated in humans, meaning that partial immunologic recognition or confusing serologic patterns may occur. These complexities underscore why molecular assays and genomic characterization are increasingly central to detection of novel influenza viruses and to accurate classification during unusual outbreaks. When suspicion for a novel influenza strain exists—especially in the setting of swine exposure, atypical clinical severity patterns, or local clusters—public health collaboration becomes essential. Depending on jurisdiction, state, regional, or national public health laboratories may be able to perform advanced molecular testing, including genomic sequencing, to determine subtype, identify reassortment patterns, and detect novel influenza viruses.[52] Such analysis supports not only the care of the individual patient, by clarifying etiology and guiding infection control, but also population-level response by informing surveillance, contact tracing, and risk communication. Thus, optimal evaluation of suspected H1N1 spans bedside triage and routine diagnostics, targeted respiratory sampling with molecular confirmation, and, when indicated, linkage to public health laboratory capacity for variant detection and genomic investigation.[48][49][50][51][52]

Treatment / Management

Management of H1N1 influenza incorporates principles that broadly apply to influenza A infections while recognizing that important modifications may be required when dealing with zoonotic variants or settings in which animal-to-human transmission is ongoing. In routine human seasonal transmission, case management focuses on early identification, appropriate antiviral

therapy for eligible patients, supportive care, prevention of complications, and interruption of transmission within households and healthcare environments. In contrast, when H1N1 activity is driven by variants of zoonotic origin, a comprehensive prevention-first framework becomes central, because the most effective method of reducing human disease burden is to prevent viral amplification in swine populations, limit spillover into humans, and thereby avert the subsequent development of sustained human-to-human transmission. This approach requires alignment between veterinary public health, occupational health, laboratory surveillance, and clinical care, and it emphasizes that control efforts are not confined to bedside therapeutics but extend to upstream interventions that reduce opportunities for reassortment, antigenic change, and outbreak initiation. Prevention of swine influenza in pigs is therefore a foundational pillar of H1N1 risk reduction when zoonotic reservoirs and spillover pathways are relevant. Preventing influenza outbreaks within swine herds relies on integrated facility management, herd management, and vaccination strategies, each targeting distinct points in the transmission chain. Facility management aims to reduce environmental conditions that favor viral persistence and rapid dissemination by implementing robust cleaning and disinfection practices, controlling temperature and ventilation, and applying biosecurity measures designed to limit introduction of pathogens into enclosed animal populations. These measures are intended to reduce environmental viral load and diminish the probability that susceptible pigs are repeatedly inoculated through contaminated surfaces or aerosolized secretions. Herd management complements facility controls by reducing contact rates and exposure intensity within and between groups. Measures such as avoiding overcrowding, optimizing stocking density, and separating animals by age or production stage can reduce the effective reproductive number of influenza within herds. Quarantine of animals exhibiting influenza-like illness away from unexposed groups further reduces onward spread and can limit the duration and magnitude of outbreaks. Vaccination is a critical third component that can reduce clinical disease, lower viral shedding, and attenuate outbreak severity; however, vaccination alone is unlikely to be fully protective in the absence of supportive facility and herd management measures, particularly when antigenic drift or mismatch between vaccine strains and circulating viruses reduces vaccine effectiveness.[53][54][55][56] In this respect, vaccination should be understood as one element within a layered prevention model rather than a stand-alone solution, because spillover risk is driven not only by swine infection presence but also by viral load, exposure opportunities, and the operational realities of animal movement and mixing. Without complementary prevention and mitigation measures, vaccinations alone may not effectively limit swine influenza spillover events.

Preventing swine-to-human transmission is the second major pillar and has immediate relevance to occupational and environmental exposure settings. Reducing influenza incidence within swine populations decreases spillover risk, but it does not eliminate it; therefore, specific strategies to reduce human exposure during swine outbreaks are equally important. Swine are notable because they can be infected by both avian and human influenza strains, a feature that has contributed to the description of pigs as “mixing vessels.” In such hosts, co-infection can enable viral reassortment and antigenic shifts, potentially generating novel strains with altered surface proteins and enhanced capacity to infect humans.[57] This is not merely a theoretical concern: the presence of multiple influenza lineages in animal populations increases the probability that reassortment will occur and that strains with new antigenic profiles will emerge in contexts where routine immune defenses in humans may offer limited protection. Consequently, preventing spillover is not only a matter of reducing immediate human infection risk but also a strategy to minimize the ecological opportunities that drive viral evolution toward human adaptability. In practice, swine-to-human transmission has been most frequently documented among individuals with close occupational or repeated contact with pigs, including farmers, pork handlers, and veterinarians.[58] In these groups, preventive interventions are appropriately framed as workplace safety measures. Use of face masks during contact with infected animals is strongly encouraged, particularly because droplet and aerosol pathways are central to influenza spread and because masks have demonstrated utility in reducing influenza transmission under conditions of close-range exposure.[59] Beyond masking, strict adherence to hand hygiene is emphasized, given that contaminated hands can mediate mucosal inoculation after contact with respiratory secretions or contaminated surfaces. These measures can be extended to a broader set of individuals with elevated exposure risk in agricultural or animal exhibition settings and can be reinforced through targeted education, signage, and institutional protocols. Individuals with an increased risk of acquiring H1N1 influenza through pigs are therefore advised to apply these strategies to prevent transmission events and to reduce the probability that small occupational clusters serve as the initiating nodes for wider community spread.

Prevention of human-to-human transmission becomes critical once H1N1 is circulating in communities, and it is especially important during periods when zoonotic strains have

acquired enhanced transmissibility. The principal routes of transmission in such settings are inhalation of respiratory droplets and aerosols, mucosal contact following exposure, and fomite-mediated spread in which contaminated surfaces are touched and virus is transferred to mucosal membranes of the nose, mouth, or eyes.[60] Because the infectious period includes pre-symptomatic shedding and continues after symptom onset, interventions must be applied consistently rather than solely when individuals appear overtly ill. Public health and infection-control strategies therefore focus on reducing opportunities for viral dissemination and interrupting exposure pathways at multiple levels, including households, workplaces, schools, healthcare facilities, and public spaces. Documented prevention measures include frequent handwashing with soap and water or use of alcohol-based sanitizers, as well as environmental cleaning and disinfection of frequently touched surfaces in household, hospital, and public settings, commonly using a diluted bleach solution where appropriate.[61] These interventions address both direct and indirect transmission pathways by reducing viral contamination and limiting mucosal inoculation following contact. Behavioral guidance during outbreaks additionally emphasizes the importance of self-isolation when symptomatic, avoiding crowded settings and public transportation, and seeking medical evaluation when influenza-like symptoms occur in areas with ongoing transmission. Such measures serve both individual and population-level goals by reducing exposure of vulnerable individuals and decreasing the effective reproduction number. Communication strategies should also address common misconceptions to maintain public confidence and ensure that preventive behavior is grounded in accurate understanding of transmission mechanisms.

Vaccination represents a central preventive strategy for reducing susceptibility and mitigating severity at the population level, and its implementation during outbreaks is often a defining component of response planning. During the 2009 H1N1 pandemic, a vaccine was approved by the United States Food and Drug Administration, supported by studies from the National Institutes of Health indicating that a single dose could generate protective antibodies within approximately 10 days.[62][63] This evidence-informed pathway—from immunogenicity studies to emergency regulatory authorization—illustrates how vaccine development and deployment can function as a principal population-level countermeasure during influenza pandemics. Vaccination guidance also requires careful attention to contraindications and clinical timing. Individuals with a prior severe allergic reaction to influenza vaccination are typically contraindicated for vaccination, while persons who are moderately to severely ill, with or without fever, are generally advised to defer vaccination until recovery or until they are asymptomatic, to optimize immune response and avoid confusion between vaccine-related symptoms and evolving illness. In outbreak settings, vaccination policy also involves prioritization of high-risk groups, healthcare workers, and individuals in critical infrastructure roles, while maintaining transparent communication about access, scheduling, and expected benefits. Treatment of infected patients is guided by illness severity, risk of progression, and timing of presentation relative to symptom onset. Mild-to-moderate disease in otherwise healthy individuals is often self-limited and can be managed in the outpatient setting with rest, oral hydration, and symptomatic measures aimed at relieving fever, pain, and upper respiratory discomfort. Antipyretics such as paracetamol/acetaminophen are commonly used to control fever and associated malaise. Symptomatic therapies may include antihistamines for rhinitis and nasal congestion and simple analgesics, including non-steroidal anti-inflammatory drugs or paracetamol/acetaminophen, for headache, myalgia, and arthralgia. Clinical counseling in outpatient care should emphasize maintenance of adequate hydration, recognition of warning signs (such as worsening dyspnea, persistent high fever, confusion, or chest pain), and the importance of limiting contact with others during the infectious period. Appropriate home management also includes advice regarding infection prevention within households, particularly when vulnerable contacts are present, such as infants, older adults, pregnant individuals, or those with chronic diseases.

Patients with progressive symptoms, significant comorbidity, or clinical features suggesting impending decompensation should be managed in an inpatient setting where physiologic monitoring and escalation to intensive support can be provided. In such cases, management priorities include early recognition of respiratory compromise, prevention of shock, and identification of secondary bacterial infection. Hospital-based care may require intravenous hydration, correction of electrolyte abnormalities, and early empiric antibiotics when bacterial coinfection is suspected based on clinical, radiographic, or laboratory findings. Close monitoring for sepsis and multiorgan dysfunction is warranted, particularly in high-risk groups and in patients presenting late with rapidly progressive pneumonia. When influenza-associated pneumonia evolves into acute respiratory distress syndrome (ARDS), respiratory support becomes the dominant therapeutic requirement. Non-invasive ventilatory support may be considered in selected patients with preserved mental status and manageable secretions, but invasive mechanical ventilation is often required for severe hypoxemic respiratory failure. In the most severe cases, refractory hypoxemia may necessitate extracorporeal membrane oxygenation (ECMO), which has been used in severe H1N1-induced ARDS

as an advanced rescue modality [64]. From a clinical systems perspective, this underscores the importance of early ICU triage, lung-protective ventilation protocols, and access to regional referral pathways for ECMO-capable centers during surges. Antiviral therapy is a key disease-modifying intervention and is most effective when administered early in the course of illness. Clinicians should be aware that early antiviral treatment, particularly when initiated within approximately 72 hours of symptom onset, may reduce the probability of severe disease and decrease mortality risk in appropriate patients. This emphasis on early treatment is grounded in the pathobiology of influenza, in which viral replication peaks early, and clinical deterioration may follow a sequence in which viral injury and immune responses intensify over several days. Thus, antiviral therapy is most effective when started before extensive lower respiratory involvement and systemic inflammatory amplification have occurred. In addition to early initiation, appropriate antiviral selection is essential. Neuraminidase inhibitors remain central to H1N1 treatment strategies, and oral oseltamivir, intravenous zanamivir, and intravenous peramivir have each been documented to reduce the effects of H1N1 influenza when administered within 48 hours of symptom onset, with potential benefit in high-risk or hospitalized patients even when initiated later depending on severity.[65][66][67] In outbreak settings, antivirals may also play a prophylactic role for high-risk exposures when vaccination is unavailable, contraindicated, or expected to be insufficiently protective.

Oseltamivir, an oral neuraminidase inhibitor, is widely used for treatment and has been associated with reduced inpatient readmission rates and mortality in influenza, supporting its role as a recommended chemoprophylaxis option during H1N1 outbreaks in appropriate contexts.[68][69] Its clinical utility lies in inhibiting neuraminidase-mediated viral release from infected cells, thereby limiting viral propagation to neighboring respiratory epithelium. While generally well tolerated, oseltamivir is associated with predictable adverse effects that should be incorporated into patient counseling and clinical decision-making. Common side effects include gastrointestinal symptoms such as nausea and vomiting, headache, and skin reactions including atopic dermatitis and urticaria.[70][71][72] Rare but clinically significant adverse reactions have been reported, including Stevens–Johnson syndrome, hepatobiliary enzyme derangement, sporadic transient neuropsychiatric events, and gastrointestinal bleeding.[70][71][72] Because risk tolerance and vulnerability vary across populations, prescribers should exercise caution when treating individuals at higher risk of complications from these adverse events and should provide clear guidance on when to seek medical attention for severe rash, jaundice, unusual behavioral changes, or persistent gastrointestinal symptoms. The benefit–risk balance is typically favorable in high-risk influenza, but careful assessment strengthens safety and adherence. Zanamivir is another neuraminidase inhibitor that has particular relevance for hospitalized patients who cannot tolerate oral oseltamivir or for whom oral administration is not feasible due to vomiting, impaired absorption, or critical illness.[73][74] Intravenous administration can be advantageous in severe cases where enteral pharmacokinetics are uncertain. Adverse effects are commonly mild, with headache often reported, while bronchospasm has been described rarely.[75] These safety considerations shape patient selection and monitoring, especially in individuals with underlying reactive airway disease. Zanamivir is contraindicated in individuals with hypersensitivity to its components and in those with severe milk protein allergy.[76] Importantly, zanamivir and oseltamivir may be used for prophylaxis in selected populations—such as older adults or immunocompromised patients—when vaccination is contraindicated, recognizing that risk stratification and exposure assessment should guide prophylactic decisions.[66][77] From a public health perspective, these options can be integrated into outbreak control measures in high-risk settings such as long-term care facilities or transplant units, where the consequences of transmission are severe.

Peramivir, developed as an intravenous neuraminidase inhibitor option, provides an additional alternative for high-risk patients and those requiring parenteral therapy. Clinical data suggest fever alleviation comparable to oseltamivir, supporting its role as a therapeutic option in appropriate hospitalized or high-risk contexts.[78][79] Post-marketing experience has reported generally mild adverse effects, including diarrhea and abnormal behavior, with rare observations of neutropenia and leukopenia.[80] As with other antivirals, clinicians should interpret these effects in the context of the patient's baseline hematologic status and concurrent therapies, particularly in those with immunosuppression or preexisting cytopenias. Antiviral resistance surveillance is also relevant to clinical decision-making and outbreak planning. A systematic review pooling analyses of influenza resistance to neuraminidase inhibitors reported approximately 2.6% resistance among influenza samples to oseltamivir, with 0% resistance reported to zanamivir and 0% to peramivir in the pooled data.[81] While resistance rates are context-dependent and can vary over time and geography, these findings underscore the importance of maintaining laboratory capacity for resistance testing and of considering resistance in patients with persistent symptoms despite therapy. Individuals who remain symptomatic after 10 days of treatment should be evaluated for secondary

infections and may warrant assessment for antiviral resistance, particularly if they are immunocompromised or have prolonged viral shedding [61]. Supportive care remains essential across all severity levels and is particularly decisive in severe disease. Supportive measures include maintenance of oxygenation, fluid balance, nutrition, and control of fever and pain, while monitoring complications such as bacterial pneumonia, sepsis, myocarditis, and renal impairment. Antibiotic therapy is not routinely indicated for uncomplicated viral influenza but becomes appropriate when clinical evidence suggests bacterial coinfection, such as focal consolidation on imaging, marked leukocytosis, purulent sputum, or hemodynamic instability consistent with sepsis. In severe influenza pneumonia, clinicians must balance fluid resuscitation for shock with the risk of worsening pulmonary edema in ARDS, often guided by dynamic hemodynamic assessment and careful monitoring of oxygenation and lung mechanics. The use of non-invasive ventilation may reduce intubation risk in selected cases, but clinicians should maintain a low threshold for intubation when respiratory fatigue, altered mental status, or worsening gas exchange occurs, because delayed intubation in progressive ARDS can increase mortality. When invasive ventilation is required, lung-protective strategies are critical to reduce ventilator-induced lung injury, and adjunctive measures such as prone positioning may be used as indicated by severity and institutional protocols. ECMO is reserved for refractory hypoxemia or hypercapnia despite optimized conventional management and requires specialized expertise and systems support [64].

Public health prevention and clinical treatment intersect in the management of high-risk populations, where early intervention yields disproportionate benefit. This is especially evident in pregnancy, which was identified as a major risk factor for complications during the 2009 H1N1 pandemic. Pregnant women who contract H1N1 are at increased risk of severe disease, plausibly due to hormonal and inflammatory response dysregulation and physiologic changes in cell-mediated immunity that support fetal tolerance but may reduce antiviral responsiveness.[82][83] Pregnancy is also associated with changes in respiratory mechanics and oxygen consumption that can narrow physiologic reserve during pneumonia. Adverse neonatal outcomes have been reported at higher frequency among pregnant patients with H1N1, including preterm birth and intrauterine growth restriction.[69] These risks underpinned strong recommendations during the 2009 pandemic from the United States Centers for Disease Control and Prevention and the World Health Organization for vaccination of all pregnant women as a preventive measure. Antiviral therapy is similarly emphasized in this population, with oseltamivir frequently used in pregnancy and associated with reduced severe illness when administered within 48 hours of symptom onset.[84] Zanamivir has also demonstrated safety data for H1N1 influenza, providing additional therapeutic options when clinically appropriate [85]. Clinical care for pregnant patients should therefore prioritize early testing, early initiation of antivirals when influenza is suspected, close monitoring for respiratory deterioration, and coordinated obstetric collaboration, particularly in the second and third trimesters when risk is heightened.[39][47] The overarching management strategy for H1N1 influenza thus integrates prevention at multiple levels with patient-centered clinical care. At the source, prevention in pigs reduces the reservoir burden and limits the opportunities for reassortment and spillover.[53][54][55][56] At the interface, occupational protections and hygiene practices reduce the probability of swine-to-human transmission, especially among farmers and veterinarians.[58][59] At the community level, hand hygiene, environmental disinfection, self-isolation when symptomatic, and vaccination reduce human-to-human transmission and protect vulnerable populations.[60][61][62][63] Within clinical care, severity-based triage ensures that mild illness is managed safely at home while high-risk or deteriorating patients receive inpatient monitoring and advanced respiratory support when necessary, including mechanical ventilation and ECMO for refractory ARDS [64]. Antiviral therapy with neuraminidase inhibitors remains central, with oseltamivir, zanamivir, and peramivir providing complementary options across outpatient and inpatient settings, and with resistance surveillance and reassessment for secondary infection guiding ongoing management in prolonged illness.[65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81] Finally, special populations such as pregnant patients require proactive preventive and therapeutic strategies due to elevated risk of complications and adverse perinatal outcomes.[69][82][83][84][85] When these elements are implemented in a coordinated fashion—supported by laboratory diagnostics, public health surveillance, and clear risk communication—H1N1 influenza can be managed effectively in both endemic and outbreak contexts, with reduced morbidity, mortality, and transmission.

Differential Diagnosis

The differential diagnosis for suspected H1N1 influenza is necessarily broad because the syndrome it produces—acute febrile respiratory illness with systemic symptoms and occasional gastrointestinal manifestations—overlaps with numerous viral, bacterial, and opportunistic conditions. In routine ambulatory settings, distinguishing H1N1 from other common viral respiratory infections is often clinically challenging without laboratory confirmation, particularly early in

the course when upper respiratory findings predominate. The differential includes viral infections such as COVID-19, adenovirus, human parainfluenza viruses and other parainfluenza virus infections, and seasonal influenza strains, all of which can present with fever, cough, rhinorrhea, sore throat, and constitutional symptoms. Additional viral etiologies may be considered depending on exposure context and clinical phenotype, including HIV-related acute retroviral syndrome, cytomegalovirus infection, arenavirus infection, echovirus infection, and hantavirus pulmonary syndrome, particularly when severe respiratory compromise or atypical systemic features occur. In travel- or region-linked presentations, dengue may also enter the differential, especially when fever and myalgia are prominent and respiratory symptoms are not initially dominant. Lower respiratory involvement broadens the differential further, as influenza can mimic or precipitate conditions characterized by hypoxemia and diffuse pulmonary inflammation. Acute respiratory distress syndrome may represent a downstream manifestation of severe H1N1 or an alternative endpoint from other infectious or noninfectious causes, requiring clinicians to maintain a parallel diagnostic approach that evaluates etiologies while simultaneously providing supportive respiratory care. Legionnaires disease is a key bacterial consideration because it can present with fever, cough, dyspnea, and systemic symptoms, and may be associated with extrapulmonary features such as gastrointestinal complaints. Atypical bacterial pneumonias, including Mycoplasma pneumoniae and Chlamydia pneumoniae infections, may mimic influenza-like illness, particularly when cough is persistent and imaging shows patchy infiltrates. In immunocompromised patients or those with advanced chronic illness, opportunistic infections must be considered, including Pneumocystis jirovecii pneumonia and cryptococcal pneumonia infection, as these entities can present with progressive dyspnea, hypoxemia, and diffuse radiographic abnormalities.

Among the conditions listed, the viral infections most likely to resemble H1N1 influenza clinically are COVID-19, seasonal influenza strains, and parainfluenza virus infections, given shared transmission routes and similar symptom clusters. COVID-19 may be differentiated by epidemiologic context, anosmia in some cases, and varied systemic involvement, but substantial overlap persists. Seasonal influenza is frequently indistinguishable on clinical grounds alone, reinforcing the importance of nucleic acid testing when subtype identification has implications for surveillance or outbreak management. Parainfluenza viruses may present similarly but are often distinguished by age distribution and clinical syndromes such as croup in children, though adult pneumonia can occur. Ultimately, accurate differentiation depends on a combination of exposure history, local epidemiology, radiographic assessment when pneumonia is suspected, and pathogen-specific diagnostic testing to guide treatment decisions and infection-control measures.

Prognosis

The prognosis of H1N1 influenza is shaped by host factors, timing of antiviral therapy, and the development of respiratory and systemic complications. During the 2009 pandemic, infection with pandemic H1N1 influenza was associated with an overall mortality of approximately 1%, although risk was not evenly distributed across populations.[86] Epidemiologic patterns suggested that individuals aged 50 years and older had a lower risk of infection compared with younger age groups, while hospitalization rates were highest among children aged five years or younger and among those between five and fourteen years of age. Severe disease was disproportionately observed in individuals with chronic comorbidities, reflecting reduced physiologic reserve and vulnerability to viral pneumonia and secondary complications. In clinical practice, prognostic evaluation is supported by laboratory indicators of severity. Severe cases were associated with elevated lactate dehydrogenase, creatinine phosphokinase, and C-reactive protein levels, along with lymphopenia, findings that collectively suggest substantial inflammatory activation, tissue injury, and impaired immune cell profiles.[87][88] These markers are not specific to H1N1, but they can aid risk stratification when interpreted alongside respiratory status and imaging findings. Prognostic variables linked to death or intensive care unit admission include diabetes, exposure to corticosteroid therapy, histamine-2 receptor use, and morbid obesity, as well as the occurrence of secondary cardiovascular and bacterial complications.[89] These factors likely reflect both baseline risk and modifiable clinical pathways, such as bacterial superinfection and decompensation of cardiovascular function, which can transform a primarily respiratory infection into multisystem failure. Timing of antiviral therapy emerges repeatedly as a modifiable determinant of outcome. In a study of 1,651 patients during the 2009 pandemic, delayed administration of oseltamivir beyond five days was independently associated with hospitalization, ICU admission, and increased odds of mortality.[90] This finding aligns with the biological reality that influenza viral replication peaks early, and that delayed therapy may occur after inflammatory injury has become established. Taken together, the prognosis for H1N1 is favorable for many healthy individuals with uncomplicated infection, yet it becomes substantially less favorable when comorbidities, late presentation, or complications such as bacterial pneumonia and cardiovascular involvement are present, reinforcing

the value of early recognition and timely intervention.[86][89][90]

Complications

Complications of H1N1 influenza span acute respiratory deterioration, systemic organ involvement, and longer-term sequelae in survivors of critical illness. During the 2009 pandemic, the dominant burden of complications was respiratory. The pandemic strain most commonly led to pneumonia and exacerbation of chronic pulmonary disease, with acute respiratory distress syndrome occurring less frequently but carrying high morbidity when present.[91] Viral pneumonia can progress rapidly, particularly in high-risk individuals, and may lead to hypoxemic respiratory failure requiring mechanical ventilation. Exacerbations of underlying conditions such as asthma or chronic obstructive pulmonary disease can further impair ventilation and predispose patients to hospitalization even when primary viral injury is moderate. Cardiovascular complications and secondary bacterial infections represent important amplifiers of poor outcomes. Secondary bacterial pneumonia can complicate the clinical course by producing consolidation, sepsis, and refractory hypoxemia, while cardiovascular involvement may manifest through demand ischemia, decompensated heart failure, or myocarditis, thereby worsening shock and organ perfusion.[88] Such complications are clinically consequential because they often emerge after initial influenza symptoms and can drive a second phase of deterioration, emphasizing the need for reassessment when patients worsen after transient improvement.

Neurologic complications have also been reported and display heterogeneous presentations, including seizures, focal neurologic deficits, Guillain–Barré syndrome, and myositis.[92] These manifestations may reflect direct or immune-mediated mechanisms and can occur across age groups, sometimes complicating disposition decisions even when respiratory symptoms are improving. In addition, survivors of severe H1N1 disease, particularly those who experienced ARDS, may face long-term functional and psychological consequences. One year after H1N1-related ARDS, patients demonstrated higher exertional dyspnea scores, lower rates of returning to work, and increased anxiety and depression compared with individuals who did not develop H1N1-related ARDS.[93] These findings underscore that the burden of H1N1 is not confined to the acute episode; rather, prolonged recovery, reduced functional capacity, and mental health sequelae can persist, supporting the importance of timely treatment and robust rehabilitation planning to mitigate both short- and long-term complications.[91][93]

Patient Education

Because H1N1 influenza is primarily transmitted through respiratory droplets and contaminated secretions, preventive education centers on personal hygiene, respiratory etiquette, and environmental controls that reduce exposure to infectious particles. Consistent hand hygiene is a foundational intervention and should be emphasized in public messaging and clinical counseling. Regular handwashing with soap and water, antiseptic hand wash, or alcohol-based hand rubs reduces the likelihood of self-inoculation after contact with contaminated surfaces and is particularly important before any activity involving hand-to-face contact.[61] In settings of high transmission risk, promoting mask use can reduce droplet dispersion from infected individuals and lower exposure for susceptible contacts, especially in crowded indoor environments or during outbreaks. Patient education should also include instruction on cough and sneeze etiquette, such as covering the mouth and nose with a tissue or elbow crease and promptly disposing of tissues, alongside social distancing measures to minimize close-range exposure to respiratory secretions.[94] These behaviors are especially important because influenza can be contagious shortly before symptom onset and during the early symptomatic period, meaning that individuals who "feel only mildly ill" may still transmit infection efficiently. Environmental hygiene complements these strategies: disinfecting contaminated surfaces using agents such as alcohol, sodium hypochlorite, or quaternary ammonia compounds can reduce fomite-mediated transmission in households, schools, workplaces, and healthcare settings.[95] Education should also promote timely healthcare seeking for high-risk individuals and clear guidance on self-isolation during illness to reduce spread. Framing prevention as a set of layered, practical actions—vaccination when available, hand hygiene, masking in appropriate contexts, and environmental cleaning—improves adherence and supports community-level reduction in transmission.

Enhancing Healthcare Team Outcomes

H1N1 influenza is highly infectious and can spread rapidly through human-to-human transmission, and in certain contexts through contact with pigs carrying influenza viruses. Because clinical deterioration can occur quickly in vulnerable individuals, optimal outcomes depend on coordinated interprofessional care that links timely diagnosis, appropriate infection control, early antiviral therapy when indicated, and proactive risk stratification. Effective team-based management begins with awareness of high-risk populations, including children, older adults, immunocompromised individuals, pregnant women, and patients with chronic medical conditions, who are more likely to develop severe disease and complications.[96] Early triage protocols that incorporate risk factors and physiologic markers such as oxygen saturation support timely escalation to hospital care when warranted. Clinicians across care settings—including primary care physicians, pharmacists, and nurse

practitioners—play central roles in prevention by advocating vaccination for children and adults at risk. Strong emphasis is placed on vaccination for pregnant women because of the elevated risks of maternal morbidity, mortality, and adverse fetal outcomes.[96] In community settings, school health systems are also important, particularly during outbreaks. In emergency situations, the school nurse, working collaboratively with school authorities, may contribute to assessing whether school closure or other mitigation strategies are needed when H1N1 cases occur.[97] Such decisions require balanced consideration of transmission dynamics, operational feasibility, and the broader social impact of closures.

Family-level engagement is similarly important. Parents should be encouraged to vaccinate children against H1N1 and to implement self-isolation when infection is suspected or confirmed, limiting exposure to others. Pharmacists contribute uniquely in many jurisdictions by administering vaccines, supporting medication counseling, and reinforcing public health messaging during outbreaks. In hospitals, nursing staff have a pivotal role in infection control and clinical monitoring. Patients should be placed in single isolation rooms with appropriate airborne precautions when indicated, and strict measures to prevent exposure to bodily fluids and aerosols generated during coughing should be implemented. Limiting the number of healthcare personnel exposed, ensuring consistent hand hygiene, and maintaining correct use of personal protective equipment reduce nosocomial transmission risk. Finally, open communication across disciplines—nursing, medicine, pharmacy, infection prevention, laboratory services, and public health—improves coordination of diagnostics, cohorting decisions, antiviral stewardship, and escalation pathways, thereby reducing morbidity and mortality associated with H1N1 influenza.[98]

Conclusion:

H1N1 influenza remains a critical public health concern due to its capacity for rapid global dissemination and severe clinical outcomes in vulnerable populations. The 2009 pandemic demonstrated how genetic reassortment among swine, avian, and human influenza strains can produce a virus capable of sustained human-to-human transmission, overwhelming healthcare systems and causing significant mortality. Lessons from this event emphasize that pandemic preparedness must integrate early detection, robust laboratory capacity, and coordinated response strategies. Vaccination continues to be the most effective preventive measure, complemented by antiviral therapy for high-risk and hospitalized patients. However, prevention cannot be confined to human health alone; controlling influenza in swine populations and reducing occupational exposure are essential to minimize opportunities for viral evolution and spillover. The One Health approach—linking veterinary and human surveillance—offers a framework for early identification of novel strains and timely intervention. Ultimately, reducing the impact of H1N1 and future influenza threats requires sustained investment in global surveillance networks, public health infrastructure, and clear risk communication to counter misinformation and promote adherence to preventive measures. By applying these lessons, health systems can mitigate morbidity, mortality, and socioeconomic disruption associated with influenza pandemics..

References:

1. Hackett S, Hill L, Patel J, Ratnaraja N, Ifeyinwa A, Farooqi M, Nusgen U, Debenham P, Gandhi D, Makwana N, Smit E, Welch S. Clinical characteristics of paediatric H1N1 admissions in Birmingham, UK. Lancet (London, England). 2009 Aug 22:374(9690):605. doi: 10.1016/S0140-6736(09)61511-7.
2. Cao B, Li XW, Mao Y, Wang J, Lu HZ, Chen YS, Liang ZA, Liang L, Zhang SJ, Zhang B, Gu L, Lu LH, Wang DY, Wang C, National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. The New England journal of medicine. 2009 Dec 24:361(26):2507-17. doi: 10.1056/NEJMoa0906612.
3. Kshatriya RM, Khara NV, Ganjiwale J, Lote SD, Patel SN, Paliwal RP. Lessons learnt from the Indian H1N1 (swine flu) epidemic: Predictors of outcome based on epidemiological and clinical profile. Journal of family medicine and primary care. 2018 Nov-Dec:7(6):1506-1509. doi: 10.4103/jfmpc.jfmpc_38_18.
4. Mena I, Nelson MI, Quezada-Monroy F, Dutta J, Cortes-Fernández R, Lara-Puente JH, Castro-Peralta F, Cunha LF, Trovão NS, Lozano-Dubernard B, Rambaut A, van Bakel H, García-Sastre A. Origins of the 2009 H1N1 influenza pandemic in swine in Mexico. eLife. 2016 Jun 28:5():. pii: e16777. doi: 10.7554/eLife.16777.
5. Lewis NS, Russell CA, Langat P, Anderson TK, Berger K, Bielejec F, Burke DF, Dudas G, Fonville JM, Fouchier RA, Kellam P, Koel BF, Lemey P, Nguyen T, Nuansrichy B, Peiris JM, Saito T, Simon G, Skepner E, Takemae N, ESNIP3 consortium, Webby RJ, Van Reeth K, Brookes SM, Larsen L, Watson SJ, Brown IH, Vincent AL. The global antigenic diversity of swine influenza A viruses. eLife. 2016 Apr 15:5():e12217. doi: 10.7554/eLife.12217.
6. Mancera Gracia JC, Van den Hoecke S, Saelens X, Van Reeth K. Effect of serial pig passages on the adaptation of an avian H9N2 influenza virus to swine. PloS one. 2017:12(4):e0175267. doi: 10.1371/journal.pone.0175267.

7. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bulletin of the history of medicine. 2002 Spring:76(1):105
8. Doshi P. The elusive definition of pandemic influenza. Bulletin of the World Health Organization. 2011 Jul 1:89(7):532-8. doi: 10.2471/BLT.11.086173.
9. Lei H, Li Y, Xiao S, Lin CH, Norris SL, Wei D, Hu Z, Ji S. Routes of transmission of influenza A H1N1, SARS CoV, and norovirus in air cabin: Comparative analyses. Indoor air. 2018 May:28(3):394-403. doi: 10.1111/ina.12445.
10. Keenliside J. Pandemic influenza A H1N1 in Swine and other animals. Current topics in microbiology and immunology. 2013:370():259-71. doi: 10.1007/82_2012_301.
11. Lange E, Kalthoff D, Blohm U, Teifke JP, Breithaupt A, Maresch C, Starick E, Fereidouni S, Hoffmann B, Mettenleiter TC, Beer M, Vahlenkamp TW. Pathogenesis and transmission of the novel swine-origin influenza virus A/H1N1 after experimental infection of pigs. The Journal of general virology. 2009 Sep:90(Pt 9):2119-23. doi: 10.1099/vir.0.014480-0.
12. Rassy D, Smith RD. The economic impact of H1N1 on Mexico's tourist and pork sectors. Health economics. 2013 Jul:22(7):824-34. doi: 10.1002/hec.2862.
13. Nogales A, Martinez-Sobrido L, Chiem K, Topham DJ, DeDiego ML. Functional Evolution of the 2009 Pandemic H1N1 Influenza Virus NS1 and PA in Humans. Journal of virology. 2018 Oct 1:92(19):. doi: 10.1128/JVI.01206-18.
14. Tapia R, García V, Mena J, Bucarey S, Medina RA, Neira V. Infection of novel reassortant H1N2 and H3N2 swine influenza A viruses in the guinea pig model. Veterinary research. 2018 Jul 27:49(1):73. doi: 10.1186/s13567-018-0572-4.
15. Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, Smith D, Rimmelzwaan GF, Olsen B, Osterhaus AD. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. Journal of virology. 2005 Mar:79(5):2814-22
16. Hirst GK. THE AGGLUTINATION OF RED CELLS BY ALLANTOIC FLUID OF CHICK EMBRYOS INFECTED WITH INFLUENZA VIRUS. Science (New York, N.Y.). 1941 Jul 4:94(2427):22-3
17. Zebedee SL, Lamb RA. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. Journal of virology. 1988 Aug:62(8):2762-72
18. Herrler G, Rott R, Klenk HD, Müller HP, Shukla AK, Schauer R. The receptor-destroying enzyme of influenza C virus is neuraminate-O-acetylesterase. The EMBO journal. 1985 Jun:4(6):1503-6
19. Shope RE. SWINE INFLUENZA : III. FILTRATION EXPERIMENTS AND ETIOLOGY. The Journal of experimental medicine. 1931 Jul 31:54(3):373-85
20. Kaplan MM. Relationships between animal and human influenza. Bulletin of the World Health Organization. 1969:41(3):485-6
21. Antigenic shift and drift. Nature. 1980 Feb 7:283(5747):524-5
22. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, Bandaranayake D, Breiman RF, Brooks WA, Buchy P, Feikin DR, Fowler KB, Gordon A, Hien NT, Horby P, Huang QS, Katz MA, Krishnan A, Lal R, Montgomery JM, Mølbak K, Pebody R, Presanis AM, Razuri H, Steens A, Tinoco YO, Wallinga J, Yu H, Vong S, Bresee J, Widdowson MA. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. The Lancet. Infectious diseases. 2012 Sep:12(9):687-95. doi: 10.1016/S1473-3099(12)70121-4.
23. Van Kerkhove MD, Hirve S, Koukounari A, Mounts AW, H1N1pdm serology working group. Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries. Influenza and other respiratory viruses. 2013 Sep:7(5):872-86. doi: 10.1111/irv.12074.
24. Nickol ME, Kindrachuk J. A year of terror and a century of reflection: perspectives on the great influenza pandemic of 1918-1919. BMC infectious diseases. 2019 Feb 6:19(1):117. doi: 10.1186/s12879-019-3750-8.
25. Cohen J. Swine flu pandemic. What's old is new: 1918 virus matches 2009 H1N1 strain. Science (New York, N.Y.). 2010 Mar 26:327(5973):1563-4. doi: 10.1126/science.327.5973.1563.
26. Scholtissek C, Rohde W, Von Hoyningen V, Rott R. On the origin of the human influenza virus subtypes H2N2 and H3N2. Virology. 1978 Jun 1:87(1):13-20
27. Li X, Guo L, Liu C, Cheng Y, Kong M, Yang L, Zhuang Z, Liu J, Zou M, Dong X, Su X, Gu Q. Human infection with a novel reassortant Eurasian-avian lineage swine H1N1 virus in northern China. Emerging microbes & infections. 2019:8(1):1535-1545. doi: 10.1080/22221751.2019.1679611.
28. Chastagner A, Enouf V, Peroz D, Hervé S, Lucas P, Quéguiner S, Gorin S, Beven V, Behillil S, Leneveu P, Garin E, Blanchard Y, van der Werf S, Simon G. Bidirectional Human-Swine Transmission of Seasonal Influenza A(H1N1)pdm09 Virus in Pig Herd, France, 2018. Emerging infectious diseases. 2019

Oct:25(10):1940-1943. doi: 10.3201/eid2510.190068.
29. Scholtissek C, Bürger H, Kistner O, Shortridge KF. The nucleoprotein as a possible major factor in determining host specificity of influenza H3N2 viruses. Virology. 1985 Dec:147(2):287-94
30. Sun H, Xiao Y, Liu J, Wang D, Li F, Wang C, Li C, Zhu J, Song J, Sun H, Jiang Z, Liu L, Zhang X, Wei K, Hou D, Pu J, Sun Y, Tong Q, Bi Y, Chang KC, Liu S, Gao GF, Liu J. Prevalent Eurasian avian-like H1N1 swine influenza virus with 2009 pandemic viral genes facilitating human infection. Proceedings of the National Academy of Sciences of the United States of America. 2020 Jul 21:117(29):17204-17210. doi: 10.1073/pnas.1921186117.
31. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, Sugerman DE, Druckenmiller JK, Ritger KA, Chugh R, Jasuja S, Deutscher M, Chen S, Walker JD, Duchin JS, Lett S, Soliva S, Wells EV, Swerdlow D, Uyeki TM, Fiore AE, Olsen SJ, Fry AM, Bridges CB, Finelli L, 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. The New England journal of medicine. 2009 Nov 12:361(20):1935-44. doi: 10.1056/NEJMoa0906695.
32. Taubenberger JK, Morens DM. The pathology of influenza virus infections. Annual review of pathology. 2008:3():499-522
33. Roberts KL, Shelton H, Stilwell P, Barclay WS. Transmission of a 2009 H1N1 pandemic influenza virus occurs before fever is detected, in the ferret model. PloS one. 2012:7(8):e43303. doi: 10.1371/journal.pone.0043303.
34. De Serres G, Rouleau I, Hamelin ME, Quach C, Skowronski D, Flamand L, Boulianne N, Li Y, Carbonneau J, Bourgault A, Couillard M, Charest H, Boivin G. Contagious period for pandemic (H1N1) 2009. Emerging infectious diseases. 2010 May:16(5):783-8. doi: 10.3201/eid1605.091894.
35. Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR. Morbidity and mortality weekly report. 2009 Aug 21:58(32):893-
36. Esposito S, Daleno C, Baldanti F, Scala A, Campanini G, Taroni F, Fossali E, Pelucchi C, Principi N. Viral shedding in children infected by pandemic A/H1N1/2009 influenza virus. Virology journal. 2011 Jul 13:8():349. doi: 10.1186/1743-422X-8-349.
37. Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, Stelfox T, Bagshaw S, Choong K, Lamontagne F, Turgeon AF, Lapinsky S, Ahern SP, Smith O, Siddiqui F, Jouvet P, Khwaja K, McIntyre L, Menon K, Hutchison J, Hornstein D, Joffe A, Lauzier F, Singh J, Karachi T, Wiebe K, Olafson K, Ramsey C, Sharma S, Dodek P, Meade M, Hall R, Fowler RA, Canadian Critical Care Trials Group H1N1 Collaborative. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009 Nov 4:302(17):1872-9. doi: 10.1001/jama.2009.1496.
38. Killip MJ, Fodor E, Randall RE. Influenza virus activation of the interferon system. Virus research. 2015 Nov 2:209():11-22. doi: 10.1016/j.virusres.2015.02.003.
39. ANZIC Influenza Investigators, Webb SA, Pettilä V, Seppelt I, Bellomo R, Bailey M, Cooper DJ, Cretikos M, Davies AR, Finfer S, Harrigan PW, Hart GK, Howe B, Iredell JR, McArthur C, Mitchell I, Morrison S, Nichol AD, Paterson DL, Peake S, Richards B, Stephens D, Turner A, Yung M. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. The New England journal of medicine. 2009 Nov 12:361(20):1925-34. doi: 10.1056/NEJMoa0908481.
40. Taubenberger JK, Layne SP. Diagnosis of influenza virus: coming to grips with the molecular era. Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology. 2001 Dec:6(4):291-
41. Nin N, Sánchez-Rodríguez C, Ver LS, Cardinal P, Ferruelo A, Soto L, Deicas A, Campos N, Rocha O, Ceraso DH, El-Assar M, Ortín J, Fernández-Segoviano P, Esteban A, Lorente JA. Lung histopathological findings in fatal pandemic influenza A (H1N1). Medicina intensiva. 2012 Jan-Feb:36(1):24-31. doi: 10.1016/j.medin.2011.10.005.
42. Morris DE, Cleary DW, Clarke SC. Secondary Bacterial Infections Associated with Influenza Pandemics. Frontiers in microbiology. 2017:8():1041. doi: 10.3389/fmicb.2017.01041.
43. Shiley KT, Nadolski G, Mickus T, Fishman NO, Lautenbach E. Differences in the epidemiological characteristics and clinical outcomes of pandemic (H1N1) 2009 influenza, compared with seasonal influenza. Infection control and hospital epidemiology. 2010 Jul:31(7):676-82. doi: 10.1086/653204.
44. Carcione D, Giele C, Dowse GK, Mak DB, Goggin L, Kwan K, Williams S, Smith D, Effler P. Comparison of pandemic (H1N1) 2009 and seasonal influenza, Western Australia, 2009. Emerging infectious diseases. 2010

Sep:16(9):1388-95. doi: 10.3201/eid1609.100076.
45. Lee N, Chan PK, Lui GC, Wong BC, Sin WW, Choi KW, Wong RY, Lee EL, Yeung AC, Ngai KL, Chan MC, Lai RW, Yu AW, Hui DS. Complications and outcomes of pandemic 2009 Influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza? The Journal of infectious diseases. 2011 Jun 15:203(12):1739-47. doi: 10.1093/infdis/jir187.
46. Lemaitre M, Carrat F. Comparative age distribution of influenza morbidity and mortality during seasonal influenza epidemics and the 2009 H1N1 pandemic. BMC infectious diseases. 2010 Jun 9:10():162. doi: 10.1186/1471-2334-10-162.
47. Yu H, Feng Z, Uyeki TM, Liao Q, Zhou L, Feng L, Ye M, Xiang N, Huai Y, Yuan Y, Jiang H, Zheng Y, Gargiullo P, Peng Z, Feng Y, Zheng J, Xu C, Zhang Y, Shu Y, Gao Z, Yang W, Wang Y. Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011 Feb 15:52(4):457-65. doi: 10.1093/cid/ciq144.
48. Jernigan DB, Lindstrom SL, Johnson JR, Miller JD, Hoelscher M, Humes R, Shively R, Brammer L, Burke SA, Villanueva JM, Balish A, Uyeki T, Mustaquim D, Bishop A, Handsfield JH, Astles R, Xu X, Klimov AI, Cox NJ, Shaw MW. Detecting 2009 pandemic influenza A (H1N1) virus infection: availability of diagnostic testing led to rapid pandemic response. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011 Jan 1:52 Suppl 1():S36-43. doi: 10.1093/cid/ciq020.
49. Wood JM, Gaines-Das RE, Taylor J, Chakraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine. 1994 Feb:12(2):167-74
50. Vasoo S, Stevens J, Singh K. Rapid antigen tests for diagnosis of pandemic (Swine) influenza A/H1N1. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009 Oct 1:49(7):1090-3. doi: 10.1086/644743.
51. Salvesen HA, Whitelaw CBA. Current and prospective control strategies of influenza A virus in swine. Porcine health management. 2021 Feb 28:7(1):23. doi: 10.1186/s40813-021-00196-0.
52. Mengual-Chuliá B, Alonso-Cordero A, Cano L, Mosquera MDM, de Molina P, Vendrell R, Reyes-Prieto M, Jané M, Torner N, Martínez AI, Vila J, Díez-Domingo J, Marcos MÁ, López-Labrador FX. Whole-Genome Analysis Surveillance of Influenza A Virus Resistance to Polymerase Complex Inhibitors in Eastern Spain from 2016 to 2019. Antimicrobial agents and chemotherapy. 2021 May 18:65(6):. doi: 10.1128/AAC.02718-20.
53. Jeong EK, Bae JE, Kim IS. Inactivation of influenza A virus H1N1 by disinfection process. American journal of infection control. 2010 Jun:38(5):354-60. doi: 10.1016/j.ajic.2010.03.003.
54. Yamaya M, Nishimura H, Lusamba Kalonji N, Deng X, Momma H, Shimotai Y, Nagatomi R. Effects of high temperature on pandemic and seasonal human influenza viral replication and infection-induced damage in primary human tracheal epithelial cell cultures. Heliyon. 2019 Feb:5(2):e01149. doi: 10.1016/j.heliyon.2019.e01149.
55. Lee JH, Gramer MR, Joo HS. Efficacy of swine influenza A virus vaccines against an H3N2 virus variant. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire. 2007 Jul:71(3):207-12
56. Fablet C, Simon G, Dorenlor V, Eono F, Eveno E, Gorin S, Quéguiner S, Madec F, Rose N. Different herd level factors associated with H1N1 or H1N2 influenza virus infections in fattening pigs. Preventive veterinary medicine. 2013 Nov 1:112(3-4):257-65. doi: 10.1016/j.prevetmed.2013.07.006.
57. Ma W, Kahn RE, Richt JA. The pig as a mixing vessel for influenza viruses: Human and veterinary implications. Journal of molecular and genetic medicine : an international journal of biomedical research. 2008 Nov 27:3(1):158-66
58. Borkenhagen LK, Wang GL, Simmons RA, Bi ZQ, Lu B, Wang XJ, Wang CX, Chen SH, Song SX, Li M, Zhao T, Wu MN, Park LP, Cao WC, Ma MJ, Gray GC. High Risk of Influenza Virus Infection Among Swine Workers: Examining a Dynamic Cohort in China. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 Jul 27:71(3):622-629. doi: 10.1093/cid/ciz865.
59. Zhang L, Peng Z, Ou J, Zeng G, Fontaine RE, Liu M, Cui F, Hong R, Zhou H, Huai Y, Chuang SK, Leung YH, Feng Y, Luo Y, Shen T, Zhu BP, Widdowson MA, Yu H. Protection by face masks against influenza A(H1N1)pdm09 virus on trans-Pacific passenger aircraft, 2009. Emerging infectious diseases. 2013:19(9):1403-10. doi: 10.3201/eid1909.121765.
60. Zhang N, Li Y. Transmission of Influenza A in a Student Office Based on Realistic Person-to-Person Contact and Surface Touch Behaviour. International journal of environmental research and public health. 2018 Aug 9:15(8):. doi: 10.3390/ijerph15081699.
61. Rewar S, Mirdha D, Rewar P. Treatment and Prevention of Pandemic H1N1 Influenza. Annals

of global health. 2015 Sep-Oct:81(5):645-53. doi: 10.1016/j.aogh.2015.08.014.
62. Borse RH, Shrestha SS, Fiore AE, Atkins CY, Singleton JA, Furlow C, Meltzer MI. Effects of vaccine program against pandemic influenza A(H1N1) virus, United States, 2009-2010. Emerging infectious diseases. 2013 Mar:19(3):439-48. doi: 10.3201/eid1903.120394.
63. Centers for Disease Control and Prevention (CDC). Interim results: state-specific influenza A (H1N1) 2009 monovalent vaccination coverage - United States, October 2009-January 2010. MMWR. Morbidity and mortality weekly report. 2010 Apr 2:59(12):363-8
64. Sukhal S, Sethi J, Ganesh M, Villablanca PA, Malhotra AK, Ramakrishna H. Extracorporeal membrane oxygenation in severe influenza infection with respiratory failure: A systematic review and meta-analysis. Annals of cardiac anaesthesia. 2017 Jan-Mar:20(1):14-21. doi: 10.4103/0971-9784.197820.
65. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000 Feb 23:283(8):1016-24
66. Cheer SM, Wagstaff AJ. Zanamivir: an update of its use in influenza. Drugs. 2002:62(1):71-106
67. Kohno S, Kida H, Mizuguchi M, Shimada J, S-021812 Clinical Study Group. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrobial agents and chemotherapy. 2010 Nov:54(11):4568-74. doi: 10.1128/AAC.00474-10.
68. Sharma Y, Horwood C, Hakendorf P, Thompson C. Effectiveness of Oseltamivir in reducing 30-day readmissions and mortality among patients with severe seasonal influenza in Australian hospitalized patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2021 Mar:104():232-238. doi: 10.1016/j.ijid.2021.01.011.
69. Al-Husban N, Obeidat N, Al-Kuran O, Al Oweidat K, Bakri F. H1N1 Infection in Pregnancy; A Retrospective Study of Feto-Maternal Outcome and Impact of the Timing of Antiviral Therapy. Mediterranean journal of hematology and infectious diseases. 2019:11(1):e2019020. doi: 10.4084/MJHID.2019.020.
70. Nordstrom BL, Oh K, Sacks ST, L'Italien GJ. Skin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study. Antiviral therapy. 2004 Apr:9(2):187-95
71. Smith EV, Pynn MC, Blackford S, Leopold DJ. Stevens-Johnson syndrome secondary to oseltamivir (Tamiflu). The British journal of general practice : the journal of the Royal College of General Practitioners. 2010 Feb:60(571):133-4. doi: 10.3399/bjgp10X483292.
72. Fang S, Qi L, Zhou N, Li C. Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir: A case report. Medicine. 2018 Sep:97(38):e12497. doi: 10.1097/MD.0000000000012497.
73. Lee D, Jo H, Jang Y, Bae S, Agura T, Kang D, Kang M, Kim Y, Cho NH, Kim Y, Kang JS. Alloferon and Zanamivir Show Effective Antiviral Activity against Influenza A Virus (H1N1) Infection In Vitro and In Vivo. International journal of molecular sciences. 2022 Dec 30:24(1):. doi: 10.3390/ijms24010678.
74. Dunn CJ, Goa KL. Zanamivir: a review of its use in influenza. Drugs. 1999 Oct:58(4):761-84
75. Eiland LS, Eiland EH. Zanamivir for the prevention of influenza in adults and children age 5 years and older. Therapeutics and clinical risk management. 2007 Jun:3(3):461-5
76. Freund B, Gravenstein S, Elliott M, Miller I. Zanamivir: a review of clinical safety. Drug safety. 1999 Oct:21(4):267-81
77. Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA. 1999 Jul 7:282(1):31-5
78. Takemoto Y, Asai T, Ikezoe I, Yano T, Ichikawa M, Miyagawa S, Matsumoto J. Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013. Chemotherapy. 2013:59(5):373-8. doi: 10.1159/000362436.
79. Nakamura S, Miyazaki T, Izumikawa K, Kakeya H, Saisho Y, Yanagihara K, Miyazaki Y, Mukae H, Kohno S. Efficacy and Safety of Intravenous Peramivir Compared With Oseltamivir in High-Risk Patients Infected With Influenza A and B Viruses: A Multicenter Randomized Controlled Study. Open forum infectious diseases. 2017 Summer:4(3):ofx129. doi: 10.1093/ofid/ofx129.
80. Komeda T, Ishii S, Itoh Y, Ariyasu Y, Sanekata M, Yoshikawa T, Shimada J. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir. II: a pediatric drug use investigation. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2015 Mar:21(3):194-201. doi: 10.1016/j.jiac.2014.11.009.
81. Thorlund K, Awad T, Boivin G, Thabane L. Systematic review of influenza resistance to the

neuraminidase inhibitors. BMC infectious diseases. 2011 May 19:11():134. doi: 10.1186/1471-2334-11-134.
82. Somerville LK, Basile K, Dwyer DE, Kok J. The impact of influenza virus infection in pregnancy. Future microbiology. 2018 Feb:13():263-274. doi: 10.2217/fmb-2017-0096.
83. Littauer EQ, Esser ES, Antao OQ, Vassilieva EV, Compans RW, Skountzou I. H1N1 influenza virus infection results in adverse pregnancy outcomes by disrupting tissue-specific hormonal regulation. PLoS pathogens. 2017 Nov:13(11):e1006757. doi: 10.1371/journal.ppat.1006757.
84. Creanga AA, Johnson TF, Graitcer SB, Hartman LK, Al-Samarrai T, Schwarz AG, Chu SY, Sackoff JE, Jamieson DJ, Fine AD, Shapiro-Mendoza CK, Jones LE, Uyeki TM, Balter S, Bish CL, Finelli L, Honein MA. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstetrics and gynecology. 2010 Apr:115(4):717-726. doi: 10.1097/AOG.0b013e3181d57947.
85. Dunstan HJ, Mill AC, Stephens S, Yates LM, Thomas SH. Pregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza A/H1N1 pandemic: a national prospective surveillance study. BJOG : an international journal of obstetrics and gynaecology. 2014 Jun:121(7):901-6. doi: 10.1111/1471-0528.12640.
86. Van Kerkhove MD, Vandemaele KA, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, Carlino LO, Owen R, Paterson B, Pelletier L, Vachon J, Gonzalez C, Hongjie Y, Zijian F, Chuang SK, Au A, Buda S, Krause G, Haas W, Bonmarin I, Taniguichi K, Nakajima K, Shobayashi T, Takayama Y, Sunagawa T, Heraud JM, Orelle A, Palacios E, van der Sande MA, Wielders CC, Hunt D, Cutter J, Lee VJ, Thomas J, Santa-Olalla P, Sierra-Moros MJ, Hanshaoworakul W, Ungchusak K, Pebody R, Jain S, Mounts AW, WHO Working Group for Risk Factors for Severe H1N1pdm Infection. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS medicine. 2011 Jul:8(7):e1001053. doi: 10.1371/journal.pmed.1001053.
87. Nguyen-Van-Tam JS, Openshaw PJ, Hashim A, Gadd EM, Lim WS, Semple MG, Read RC, Taylor BL, Brett SJ, McMenamin J, Enstone JE, Armstrong C, Nicholson KG, Influenza Clinical Information Network (FLU-CIN). Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax. 2010 Jul:65(7):645-51. doi: 10.1136/thx.2010.135210.
88. Sertogullarindan B, Ozbay B, Gunini H, Sunnetcioglu A, Arisoy A, Bilgin HM, Mermit Cilingir B, Duran M, Yildiz H, Ekin S, Baran A. Clinical and prognostic features of patients with pandemic 2009 influenza A (H1N1) virus in the intensive care unit. African health sciences. 2011 Jun:11(2):163-70
89. Delgado-Rodríguez M, Castilla J, Godoy P, Martín V, Soldevila N, Alonso J, Astray J, Baricot M, Cantón R, Castro A, Gónzález-Candelas F, Mayoral JM, Quintana JM, Pumarola T, Tamames S, Sáez M, Domínguez A, CIBERESP Cases and Controls in Pandemic Influenza Working Group. Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors. The Journal of antimicrobial chemotherapy. 2012 Jul:67(7):1739-45. doi: 10.1093/jac/dks098.
90. Bellei NC, Cabeça TK, Carraro E, Goto JM, Cuba GT, Hidalgo SR, Burattini MN. Pandemic H1N1 illness prognosis: evidence from clinical and epidemiological data from the first pandemic wave in São Paulo, Brazil. Clinics (Sao Paulo, Brazil). 2013 Jun:68(6):840-5. doi: 10.6061/clinics/2013(06)19.
91. Viasus D, Oteo Revuelta JA, Martínez-Montauti J, Carratalà J. Influenza A(H1N1)pdm09-related pneumonia and other complications. Enfermedades infecciosas y microbiologia clinica. 2012 Oct:30 Suppl 4():43-8. doi: 10.1016/S0213-005X(12)70104-0.
92. Davis LE. Neurologic and muscular complications of the 2009 influenza A (H1N1) pandemic. Current neurology and neuroscience reports. 2010 Nov:10(6):476-83. doi: 10.1007/s11910-010-0135-1.
93. Luyt CE, Combes A, Becquemin MH, Beigelman-Aubry C, Hatem S, Brun AL, Zraik N, Carrat F, Grenier PA, Richard JM, Mercat A, Brochard L, Brun-Buisson C, Chastre J, REVA Study Group. Long-term outcomes of pandemic 2009 influenza A(H1N1)-associated severe ARDS. Chest. 2012 Sep:142(3):583-592. doi: 10.1378/chest.11-2196.
94. Del Rio C, Hernandez-Avila M. Lessons from previous influenza pandemics and from the Mexican response to the current influenza pandemic. Archives of medical research. 2009 Nov:40(8):677-80. doi: 10.1016/j.arcmed.2009.12.005.
95. Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for control in health care settings. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2003 Oct 15:37(8):1094-101
96. Fell DB, Sprague AE, Liu N, Yasseen AS 3rd, Wen SW, Smith G, Walker MC, Better Outcomes Registry & Network (BORN) Ontario. H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes. American journal of public health. 2012 Jun:102(6):e33-40. doi: 10.2105/AJPH.2011.300606.
97. Jackson C, Vynnycky E, Hawker J, Olowokure B, Mangtani P. School closures and influenza: systematic review of epidemiological studies. BMJ open. 2013:3(2):. doi: 10.1136/bmjopen-2012-002149.
Cauchemez S, Ferguson NM, Wachtel C, Tegnell A, Saour G, Duncan B, Nicoll A. Closure of schools during an influenza pandemic. The Lancet. Infectious diseases. 2009 Aug:9(8):473-81. doi: 10.1016/S1473-3099(09)70176-8